# Laboratory certification and test authorization

Source: https://onco.cc/terms/laboratory-certification-test-authorization/  
OnCo record `laboratory-certification-test-authorization` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Laboratory certification addresses the laboratory and its testing quality. Product authorization and evidence that a particular test use helps patients answer separate questions.

## Summary

The U.S. Clinical Laboratory Improvement Amendments program sets laboratory-quality requirements for testing human specimens. CMS distinguishes analytical oversight under that program from clinical validity, which concerns what a result means for a clinical condition. A research-use label describes intended purpose; a laboratory-developed-test description concerns how and where a test is developed and used. FDA product authorization concerns a specified product and intended use. These descriptions can coexist and do not form one universal ladder of clinical usefulness or payment.

## Fields

- Kind: Term
- Last checked: 2026-11-13
- Also known as: Clinical Laboratory Improvement Amendments; CLIA laboratory certification; CLIA certification; laboratory quality versus test authorization

## Notes

- The CMS FAQ is used here for the analytical-oversight versus clinical-validity distinction, not its historical discussion of FDA authority over laboratory-developed tests. Current procedural history is retained in the separate FDA LDT-rule record.
- An entry in FDA establishment registration or device listing does not itself mean that the facility or device is approved, cleared or authorized. Registration and product authorization are separate claims.
- Three examples separate intended uses. Validated ER immunohistochemistry in invasive breast cancer, with appropriate tissue handling, tumour-nucleus scoring and controls, has a marker-specific pathology and endocrine-treatment assessment role; it does not validate a new RNA score as a substitute. In a wholly fictional second example, assay T version 1 detects alteration M in fixed tumour tissue under rule R, and Drug A requires exactly that result in setting S. The stipulated match supplies that requirement within the exercise, without promising benefit; another specimen, result type or setting needs evidence for the changed use. A third fictional score Q combines RNA, spatial neighbourhoods and a derived culture response to propose Drug A. Reproducibility and biological support can justify research, but do not establish that Q-guided care improves outcomes against an appropriate comparator. A laboratory certificate does not supply that missing evidence. Useful research and an established clinical use can appear on different parts of one report.

## Sources

- CMS: Clinical Laboratory Improvement Amendments: https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
- CMS: CLIA analytical oversight and clinical validity (2013 FAQ; historical FDA discussion not used): https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf
- FDA: current laboratory-developed-test rule notice: https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
- FDA: research-use-only and investigational-use-only IVD guidance: https://www.fda.gov/media/87374/download
- FDA: companion diagnostics: https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics
- FDA: registration and listing do not establish authorization: https://www.fda.gov/medical-devices/device-registration-and-listing/important-reminders-about-registration-and-listing
- ASCO/CAP: ER and PR testing recommendations (2020): https://www.cap.org/wp-content/uploads/documents/erpgr_summaryrecommendations.pdf
- FDA: companion diagnostic labeling for a group of oncology products (April 2020): https://www.fda.gov/media/120340/download

## Connected records

- terms: [Analytical versus clinical validation](https://onco.cc/terms/analytical-vs-clinical-validation/), [Companion diagnostic](https://onco.cc/terms/companion-diagnostic-term/), [FDA laboratory-developed test (LDT) rule](https://onco.cc/terms/fda-ldt-rule/), [Research use only (RUO)](https://onco.cc/terms/research-use-only/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/)

---
JSON: https://onco.cc/api/v1/entities/laboratory-certification-test-authorization.json